US Spinal Muscular Atrophy Launch Readiness

Zolgensma (onasemnogene abeparvovec, Novartis, approved 2019), Evrysdi (risdiplam, Roche, approved 2020) and Spinraza (nusinersen, Biogen, approved 2016) have divided the US SMA market by patient type with six-plus years of payer precedent behind each division: Zolgensma treats essentially all newborn-screening-identified and Type 1 infants ($2.125 million one-time, gene therapy); Evrysdi has taken roughly 50% share in paediatric Type 2/3 patients under 18 on oral-route preference; Spinraza retains established adult patients while losing new starts to Evrysdi. A fourth agent cannot compete for this broad, already-segmented market — every patient type already has a defined, payer-accepted first choice.

The commercial opening is a patient segment that does not yet have a defined therapy or payer pathway: an estimated 500–700 US children treated with Zolgensma between 2019 and 2023 are now four to seven years old, and 15–20% are showing early motor plateau or functional decline — the 'Zolgensma-attenuation' hypothesis, in which transgene expression may decline as hepatocytes divide with growth. Two adjacent niches carry similar logic: non-ambulatory adult Type 2 patients (800–1,200 US patients, where upper-limb function rather than ambulation is the meaningful endpoint) and ultra-rare adult-onset Type 4 SMA (100–200 US patients, frequently misdiagnosed as LGMD or ALS before SMN1/2 testing). None of these three segments has clinical trial data or an established prior-authorization pathway today.

Because no PA pathway exists yet for any of these segments, a new entrant's pre-launch task is to build payer medical-director consensus around a new segment definition 18–24 months before approval — the payer landscape for the existing three drugs is mature, but nothing is written for a fourth. If the new agent is itself a gene therapy, it needs a Medicaid Cell and Gene Therapy Access (CGTA) outcomes-based payment structure from day one: ten states have already enrolled in the CGTA model for Zolgensma, paying an annuity of roughly $212,500 a year for ten years rather than the $2.125 million upfront list price, and Medicaid will not purchase a second multi-million-dollar gene therapy without an equivalent structure in place. The gene-therapy durability data gap, full ten-year Zolgensma follow-up not expected until 2029–2030, is itself the commercial window: a confirmed attenuation signal would open the market to a booster or combination therapy years before that data matures.

This assessment synthesises three independently-verified research angles into one pre-launch view: competitive standard-of-care positioning, target-population epidemiology, and anticipated payer posture. Every factual claim traces to a primary source: FDA approval records, peer-reviewed trial and long-term-follow-up publications, and named registry data.

SMA sources: FDA Drugs@FDA, STR1VE and NURTURE (Zolgensma), FIREFISH and SUNFISH (Evrysdi), ENDEAR and CHERISH (Spinraza), Strauss KA et al. Mol Ther 2023 Zolgensma long-term follow-up, Cure SMA gene therapy registry, and CMS CGTA SMA pilot enrolment data 2024.